What is LimFlow?
LimFlow operates at the intersection of vascular surgery and interventional cardiology, developing minimally-invasive systems designed to bypass blocked arteries in the lower limbs. By leveraging the venous system to restore oxygenated blood flow to the foot, the company addresses a critical clinical gap for patients suffering from diabetes, heart disease, and kidney failure. This innovative approach not only facilitates wound healing and pain management but also serves as a vital intervention for patients who have exhausted all other therapeutic options. As a venture-backed entity, LimFlow is positioned as a transformative force in the medtech industry, focusing on improving patient outcomes and reducing the incidence of major limb loss.
How much funding has LimFlow raised?
LimFlow has raised a total of $73.5M across 2 funding rounds:
Series C
$33.5M
Series D
$40M
Series C (2018): $33.5M with participation from Balestier, The French Sovereign investment bank, Sofinnova Partners, and Bpifrance
Series D (2022): $40M led by Longitude Capital and Soleus Capital
Key Investors in LimFlow
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. The firm acts as a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.
Bpifrance
Bpifrance is a French public investment bank that supports companies at every stage of their development through credit, guarantees, and equity. They focus on fostering innovation and international expansion for startups and mid-cap companies.
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that invests in biotechnology, medical technology, and health solutions. They pair sector expertise with flexible capital to help innovators scale and improve patient care.
What's next for LimFlow?
The infusion of capital from the latest financing round is expected to accelerate the commercialization and clinical adoption of the LimFlow system. As the company transitions from development to broader market penetration, strategic priorities will likely include expanding clinical evidence, scaling manufacturing capabilities, and navigating regulatory pathways in key global markets. By maintaining a focus on high-impact medical technology, LimFlow is well-positioned to solidify its market leadership and continue its trajectory of growth, ultimately setting a new standard of care for patients with complex vascular conditions.
See full LimFlow company page
